M21 Header Logo

Medical 21 Blog

Learn more about our breakthrough technology and how it paves the way for new successes in cardiac bypass surgery. Surgeons and care teams can discover how Medical 21’s graft can benefit patients and hospitals through cutting-edge innovations that reduce pain, infection, and scarring, which improves the patient’s quality of life while reducing overall costs to the hospital and healthcare system.

Manny Villafana
Medical 21 Blog Latest

Read Our Latest Blog

The Living Legend of Medicine, Manny Villafaña, Ph.D.Sc., received the Lifetime Achievement Award in Medical Devices for his remarkable contributions to the field

Read more

Stay up-to-date on Medical 21’s innovative cardiac bypass surgery technology by subscribing to our blog. Learn more about cardiac disease, bypass surgery, clinical trials, and case studies. Our industry experts will help keep you informed.

Manny Villafana
Dr. Manny Villafaña Honored With LSI’s 2022 Lifetime Achievement Award
Uncategorized
The Living Legend of Medicine, Manny Villafaña, Ph.D.Sc., received the Lifetime Achievement Award in Medical Devices for his remarkable contributions to the field
Read more
Medical 21 Blog Sample
Blog Post Title
Category
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex...
Read more
Medical 21 Blog Sample
Post Title
Category
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, sed do eiusmod tempor incididunt ut labore et.
Read more
Medical 21 Blog Sample
Post Title
Category
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, sed do eiusmod tempor incididunt ut labore et.
Read more
Medical 21 Blog Sample
Post Title
Category
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, sed do eiusmod tempor incididunt ut labore et. Agario...
Read more
Medical 21 Blog Sample
Post Title
Category
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, sed do eiusmod tempor incididunt ut labore et. bursa...
Read more

Subscribe to Our Blog

Stay up-to-date on Medical 21’s innovative cardiac bypass surgery technology by subscribing to our blog. Learn more about cardiac disease, bypass surgery, clinical trials, and case studies. Our industry experts will help keep you informed.

Subscription successful!

This Opportunity is Open to Everyone

Medical 21 is open to investors through Regulation A+ fundraising, which allows accredited investors and the general public alike to participate.

Learn how you can join us in reshaping the future of cardiac bypass surgery.

Invest in Medical 21

View Offering Circular

M21 Logo Footer

Follow Us:

Linkedin-in Facebook-f Twitter
The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment. The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.